​Comprehensive mendelian randomization analysis of plasma proteomics to identify new therapeutic targets for the treatment of coronary heart disease and myocardial infarction

J Transl Med. 2024 Apr 30;22(1):404. doi: 10.1186/s12967-024-05178-8.

Abstract

Background: Ischemic heart disease is one of the leading causes of mortality worldwide, and thus calls for development of more effective therapeutic strategies. This study aimed to identify potential therapeutic targets for coronary heart disease (CHD) and myocardial infarction (MI) by investigating the causal relationship between plasma proteins and these conditions.

Methods: A two-sample Mendelian randomization (MR) study was performed to evaluate more than 1600 plasma proteins for their causal associations with CHD and MI. The MR findings were further confirmed through Bayesian colocalization, Summary-data-based Mendelian Randomization (SMR), and Transcriptome-Wide Association Studies (TWAS) analyses. Further analyses, including enrichment analysis, single-cell analysis, MR analysis of cardiovascular risk factors, phenome-wide Mendelian Randomization (Phe-MR), and protein-protein interaction (PPI) network construction were conducted to verify the roles of selected causal proteins.

Results: Thirteen proteins were causally associated with CHD, seven of which were also causal for MI. Among them, FES and PCSK9 were causal proteins for both diseases as determined by several analytical methods. PCSK9 was a risk factor of CHD (OR = 1.25, 95% CI: 1.13-1.38, P = 7.47E-06) and MI (OR = 1.36, 95% CI: 1.21-1.54, P = 2.30E-07), whereas FES was protective against CHD (OR = 0.68, 95% CI: 0.59-0.79, P = 6.40E-07) and MI (OR = 0.65, 95% CI: 0.54-0.77, P = 5.38E-07). Further validation through enrichment and single-cell analysis confirmed the causal effects of these proteins. Moreover, MR analysis of cardiovascular risk factors, Phe-MR, and PPI network provided insights into the potential drug development based on the proteins.

Conclusions: This study investigated the causal pathways associated with CHD and MI, highlighting the protective and risk roles of FES and PCSK9, respectively. FES. Specifically, the results showed that these proteins are promising therapeutic targets for future drug development.

Keywords: Biomarker; Coronary heart disease; Drug target; Myocardial infarction; Protein; Proteome-wide mendelian randomization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bayes Theorem
  • Blood Proteins* / metabolism
  • Coronary Disease* / blood
  • Coronary Disease* / genetics
  • Genome-Wide Association Study
  • Humans
  • Mendelian Randomization Analysis*
  • Molecular Targeted Therapy
  • Myocardial Infarction* / blood
  • Myocardial Infarction* / genetics
  • Proprotein Convertase 9 / blood
  • Proprotein Convertase 9 / genetics
  • Proprotein Convertase 9 / metabolism
  • Protein Interaction Maps / genetics
  • Proteomics* / methods
  • Risk Factors

Substances

  • Blood Proteins
  • Proprotein Convertase 9